Allorion, Therapeutics

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

Published on 08/07/2025 at 18:00 | prnewswire.co.uk

Allorion Therapeutics Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/allorion-therapeutics-announces-exclusive-option-and-global-license-agreement-for-novel-preclinical-stage-egfr-l858r-allosteric-inhibitor-program-with-astrazeneca-302023565.html

en | boerse | 68020249 |